- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT 60 µg, RSV MAT 120 µg, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 534 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 264
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV cps2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- La Jolla, California • Long Beach, California • Denver, Colorado + 1 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- CodaVax-RSV, Normal Saline
- Biological
- Lead sponsor
- Codagenix, Inc
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
- Conditions
- Congenital Heart Disease
- Interventions
- Motavizumab, Palivizumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 1,236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 25 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease, Respiratory Syncytial Virus Infection
- Interventions
- Remdesivir, Survey Administration, Biospecimen Collection, Nasal Swab
- Drug · Other · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Houston, Texas • Seattle, Washington
- Conditions
- Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- IQuum, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,642 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Delray Beach, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- RSV Infection
- Interventions
- EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
- Interventions
- artus Influenza A/B RT-PCR Test
- Device
- Lead sponsor
- QIAGEN Gaithersburg, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Up to 6 Months
- Enrollment
- 1,177 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Years to 49 Years · Female only
- Enrollment
- 384 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV ΔNS2/Δ1313/I1314L Vaccine, RSV 6120/ΔNS2/1030s Vaccine, RSV 276 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 25 Months
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 10 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Phoenix, Arizona • North Hollywood, California + 13 more
- Conditions
- Healthy
- Interventions
- MEDI-559, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 23 Months
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 75
- States / cities
- Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Riverside, California + 15 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- S-337395, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 37
- States / cities
- Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
- Conditions
- Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
- Interventions
- PUL-042, Placebo
- Drug
- Lead sponsor
- Pulmotect, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Duarte, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
- Conditions
- Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
- Interventions
- MEDI-534
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 6 Months to 23 Months
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 30
- States / cities
- Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more
- Conditions
- Drug Safety, Respiratory Syncytial Virus Infections
- Interventions
- MDT-637
- Drug
- Lead sponsor
- MicroDose Therapeutx, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- RSV Infection, QTc Interval
- Interventions
- zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • San Antonio, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 1,586 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
- Conditions
- Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
- Interventions
- RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
- Biological · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 50
- States / cities
- Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID cp ΔM2-2 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more